Novavax, Inc. submitted an application to the U.S. FDA for Emergency Use Authorization (EUA) of its protein-based COVID-19 Vaccine, Adjuvanted for active immunization to prevent COVID-19 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a homologous and heterologous booster in adults aged 18 and older.   The application is supported by data from Novavax’ Phase 3 PREVENT-19 trial. As part of an open-label booster phase of the PREVENT-19 trial, a single booster ...